Julie Anne Roldan
Acute Care · New York, NYNPI 1588271332
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,277 of the $9,731 with a category attached, or 85.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,289 and has fallen 58.0% since, to $1,380 in 2025. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $50.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$2K
- Novo Nordisk$963
- Boehringer Ingelheim$592
- Abiomed$525
- Cvrx, Inc.$523
- plus $3K from 21 others
What the payments were for
- Consulting fees$1502%
- Travel & lodging$1,27713%
- Food & beverage$8,27785%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $2,272 |
| AstraZeneca | 38 | $1,574 |
| Novo Nordisk | 31 | $963 |
| Boehringer Ingelheim | 8 | $592 |
| Abiomed | 4 | $525 |
| Cvrx, Inc. | 3 | $523 |
| E.r. Squibb & Sons, L.L.C. | 16 | $501 |
| Boston Scientific | 5 | $470 |
| Siemens Medical Solutions USA, Inc. | 4 | $422 |
| Novartis | 19 | $325 |
| Merck | 13 | $315 |
| Alnylam Pharmaceuticals Inc. | 3 | $186 |
| Atricure, Inc. | 1 | $141 |
| Lexicon Pharmaceuticals, Inc. | 6 | $136 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| GE HealthCare | 1 | $114 |
| Medtronic | 2 | $103 |
| Pfizer | 4 | $75 |
| Paragonix Technologies, Inc. | 1 | $72 |
| Johnson & Johnson | 2 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $55 |
| Amgen | 2 | $48 |
| Briohealth Solutions, Inc. | 1 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,358
- FARXIGA$616
- Barostim Neo System$523
- JARDIANCE$480
- CARDIOMEMS$378
- Ozempic$367
- ACUSON SC2000 Diagnostic Ultrasound System$279
- Impella$207
- SYNERGY ABLATION SYSTEM$141
- CAMZYOS$138
- ONPATTRO$125
- NEXLIZET$125
- NEXLETOL$125
- BRILINTA$125
- Wegovy$125
- RESONATE$118
- WAINUA$112
How this compares
$9,731 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 99 | $92,365 |
| JardianceEmpagliflozin | 31 | $29,394 |
| OzempicSemaglutide | 15 | $17,049 |
| FarxigaDapagliflozin Propanediol | 26 | $16,682 |
| Sildenafil Citrate | 12 | $15,073 |
| Eplerenone | 41 | $3,629 |
| Cefpodoxime Proxetil | 13 | $2,757 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,629 |
| Warfarin Sodium | 177 | $2,020 |
| Pantoprazole Sodium | 92 | $1,290 |
| Cefadroxil | 14 | $1,173 |
| Carvedilol | 122 | $1,032 |
| Digoxin | 51 | $885 |
| Doxycycline Hyclate | 32 | $867 |
| Atorvastatin Calcium | 76 | $822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $325 | $92,36599 claims |
| Boehringer IngelheimJardiance | $592 | $29,39431 claims |
| Novo NordiskOzempic | $963 | $17,04915 claims |
| AstraZenecaFarxiga | $1,574 | $16,68226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in New York
- Daniel VerinaNew York$464K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Lauren Dela CruzNew York$9K
- Kristen DonchezNew York$8K
- Tracy Valerie BertizNew York$7K
- Jennifer UllmanNew York$7K
- Sara-Jane DakroubNew York$6K
- Kathryn CiccoliniNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.